Phase II study of docetaxel and cisplatin administered as three consecutive weekly infusions for advanced non-small cell lung cancer.

[1]  T. Hickish,et al.  Duration of chemotherapy in advanced non-small-cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  H. Ohmatsu,et al.  Phase I studies of cisplatin and docetaxel administered by three consecutive weekly infusions for advanced non-small cell lung cancer in elderly and non-elderly patients. , 2001, Japanese journal of clinical oncology.

[3]  J. Hainsworth,et al.  Weekly docetaxel in the treatment of elderly patients with advanced nonsmall cell lung carcinoma , 2000, Cancer.

[4]  M. Kris,et al.  Randomized Phase III Trial of Docetaxel Versus Vinorelbine or Ifosfamide in Patients With Advanced Non–Small-Cell Lung Cancer Previously Treated With Platinum-Containing Chemotherapy Regimens , 2000 .

[5]  J. Dancey,et al.  Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  S. Barni,et al.  Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: A randomized phase III study of the Italian Lung Cancer Project. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  J. Crowley,et al.  Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  J. Hainsworth,et al.  Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  R. James,et al.  Phase II study of docetaxel and cisplatin in advanced non-small-cell lung cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  M. van Glabbeke,et al.  Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: final results of a randomized study of the European Organization for Research and Treatment of Cancer Investigational Drug Branch for Breast Cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  T. Taguchi,et al.  Phase II trial of docetaxel in previously untreated advanced non-small-cell lung cancer: a Japanese cooperative study. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  V. Valero,et al.  Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  P M Ravdin,et al.  Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  O. Brodin,et al.  Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials , 1995 .

[15]  S Lippman,et al.  Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small-cell lung cancer. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  F. Invernizzi,et al.  Chemotherapy vs supportive care in advanced non-small-cell lung cancer. Results of a meta-analysis of the literature. , 1994, Chest.

[17]  J. Wanders,et al.  Docetaxel (Taxotere) is active in non-small-cell lung cancer: a phase II trial of the EORTC Early Clinical Trials Group (ECTG) , 1994, British Journal of Cancer.

[18]  M. Kris,et al.  Phase II trial of docetaxel in patients with stage III and IV non-small-cell lung cancer. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  S. Lippman,et al.  Phase II study of docetaxel for recurrent or metastatic non-small-cell lung cancer. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  P Chomy,et al.  Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  A. Oxman,et al.  Chemotherapy for advanced non-small-cell lung cancer: how much benefit is enough? , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  Dirk Schrijvers,et al.  Coping with toxicities of docetaxel (TaxotereTM) , 1993 .

[23]  Y. Shimada,et al.  Toxicity grading criteria of the Japan Clinical Oncology Group. The Clinical Trial Review Committee of the Japan Clinical Oncology Group. , 1993, Japanese journal of clinical oncology.

[24]  S. Kaasa,et al.  Polychemotherapy in advanced non small cell lung cancer: a meta-analysis , 1993, The Lancet.

[25]  J. Crowley,et al.  Evaluation of cisplatin intensity in metastatic non-small-cell lung cancer: a phase III study of the Southwest Oncology Group. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  R. Simon,et al.  Optimal two-stage designs for phase II clinical trials. , 1989, Controlled clinical trials.

[27]  P. Rocmans,et al.  A randomized study comparing a high and a standard dose of cisplatin in combination with etoposide in the treatment of advanced non-small-cell lung carcinoma. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  L. Einhorn,et al.  Random prospective study of vindesine versus vindesine plus high-dose cisplatin versus vindesine plus cisplatin plus mitomycin C in advanced non-small-cell lung cancer. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[30]  A. Gregor,et al.  Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  D. Carbone,et al.  Activity of docetaxel in platinum-treated non-small-cell lung cancer: results of a phase II multicenter trial. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  A. Carrato,et al.  Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  A. Miller,et al.  Reporting results of cancer treatment , 1981, Cancer.